Novartis’ Fabhalta Gets FDA Accelerated Approval, Becomes First Complement Inhibitor for IgAN

Fabhalta is approved for the treatment of IgAN patients who are at risk of rapid disease progression, which is indicated by a urine protein-to-creatinine ratio of at least 1.5 g/g.